P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY,...

por Weisel, K., Wadlund, A., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N., Rodriguez-Otero, P.
Publicado 2022

Expansion of CD8+CD57+ T Cells in an Immunocompetent Patient with Acute Toxoplasmosis

por García-Muñoz, R., Rodríguez-Otero, P., Galar, A., Merino, J., Beunza, J. J., Páramo, J. A., Lecumberri, R.
Publicado 2009

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY

por Rodríguez-Otero, P, San-Miguel, J, Anderson, LD, Lonial, S, Truppel-Hartmann, A, Sanford, J, Rowe, E, Campbell, TB, Munshi, N
Publicado 2022

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYEL...

por Rodríguez-Otero, P, Shah, N, Munshi, N, Berdeja, J, Jagannath, S, Finney, O, Martin, N, Agarwal, A, Rowe, E, Campbell, T, San-Miguel, J
Publicado 2022

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

por Broijl, A., van de Donk, N., Bosch, F., Mateos, M. V., Rodriguez-Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., van der Vliet, H., Kater, A.
Publicado 2022

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RE...

por van de Donk, N. W. C. J, Minnema, M C, Berdeja, J G, Oriol, A, Krishnan, A, Rodríguez-Otero, P, Askari, E, Mateos, M, Costa, L. J, Verona, R, Ma, J, Girgis, S, Yang, S, Hilder, B. W, Russell, J, Goldberg, J. D, Chari, A
Publicado 2022

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP...

por Delforge, M., Usmani, S. Z., van de Donk, N. W., Garfall, A. L., Moreau, P., Oriol, A., Nooka, A. K., Rosinol, L., Bahlis, N., Rodriguez-Otero, P., Martin, T., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Krishnan, A.
Publicado 2022

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON

por Rosinol, L., Usmani, S. Z., Bahlis, N., Krishnan, A. Y., Nooka, A. K., Oriol, A., Delforge, M., Garfall, A. L., van de Donk, N. W., Rodríguez Otero, P., Martin, T. G., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Moreau, P.
Publicado 2022

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL...

por Rodríguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.
Publicado 2023

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

por Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Publicado 2022

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

por Rodriguez-Otero, P, Dholaria, B, Askari, E, Reece, D, van de Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San-Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Publicado 2022

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

por Mateos, M, Hari, P, Bahlis, N, Chari, A, van de Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez-Otero, P, San-Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Publicado 2022

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISP...

por van de Donk, N., Rasche, L., Touzeau, C., Chari, A., Schinke, C., Minnema, M., Berdeja, J., Oriol, A., Rodriguez-Otero, P., Askari, E., Mateos, M., Costa, L., Caers, J., Krishnan, A., Vishwamitra, D., Ma, J., Qin, X., Gries, K.S., Kato, K., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J., Heuck, C., Moreau, P., San-Miguel, J.
Publicado 2023

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (B...

por van de Donk, N., Mateos, M.-V., Cohen, Y.C., Rodriguez-Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San-Miguel, J.
Publicado 2023

P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

por Tamariz-Amador, L.-E., Battaglia, A. M., Maia, C., Zherniakova, A., Guerrero, C., Zabaleta, A., Burgos, L., Botta, C., Fortuño, M.-A., Alignani, D., Blanco, L., Grande, C., Manubens, A., Arguiñano, J.-M., Gomez, C., Perez-Persona, E., Olazabal, I., Oiartzabal, I., Panizo, C., Prosper, F., San Miguel, J. F., Rodriguez-Otero, P., Martín-Sánchez, E., Paiva, B., ASOVASNA, A. V.-N. H.-H.
Publicado 2022

P862: SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR T-CELL THERAPY

por Ortiz De Landazuri, I., Oliver-Caldés, A., Español-Rego, M., Contreras, M. T., Zabaleta, A., Agulló, C., Puig, N., Cabañas, V., González-Calle, V., Jiménez, R., Inogés, S., Rodríguez-Otero, P., Martin-Antonio, B., Reguera, J. L., López-Diaz de Cerio, A., Benítez-Ribas, D., Rodríguez-Lobato, L. G., González, E. A., Rosiñol, L., Yagüe, J., Moraleda, J. M., Urbano-Ispizua, Á., Mateos, M. V., Juan, M., Paiva, B., Pascal, M., Fernández de Larrea, C.
Publicado 2022

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

por Sanoja-Flores, L., Flores-Montero, J., Garcés, J. J., Paiva, B., Puig, N., García-Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., Hernández-Martín, J., Pontes, R., Díez-Campelo, M., Millacoy, P., Rodríguez-Otero, P., Prosper, F., Merino, J., Vidriales, M. B., García-Sanz, R., Romero, A., Palomera, L., Ríos-Tamayo, R., Pérez-Andrés, M., Blanco, J. F., González, M., van Dongen, J. J. M., Durie, B., Mateos, M. V., San-Miguel, J., Orfao, A.
Publicado 2018